Creative Medical Technology expands collaboration with Greenstone Biosciences

Creative Medical Technology (CELZ) announced an expanded agreement with Greenstone Biosciences to leverage Artificial Intelligence in further developing its human induced pluripotent stem cell platform for diabetes treatment. This strategic collaboration extends the progress made on Creative Medical’s proprietary hypoimmune iPSC technology, including its iPSC-derived pancreatic islet cells. These innovative cell lines, developed from Good Manufacturing Practice grade human perinatal cells, are currently being used in clinical trials. By integrating AI-driven drug discovery, the partnership aims to identify small molecules that enhance insulin secretion, further refining the therapeutic potential of Creative Medical’s hypoimmunogenic iPSC-derived pancreatic islet cells. Additionally, the program will implement multi-gene editing to develop next generation hypoimmune iPSC lines with enhanced stealth, survival, and differentiation capabilities. These advancements will not only optimize pancreatic islet cell function but also expand the platform’s applications to other regenerative therapies, addressing critical unmet medical needs.